State Street’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-33,907
| Closed | -$9K | – | 4960 |
|
|
2022
Q3 | $9K | Hold |
33,907
| – | – | ﹤0.01% | 4898 |
|
|
2022
Q2 | $12K | Hold |
33,907
| – | – | ﹤0.01% | 4918 |
|
|
2022
Q1 | $23K | Hold |
33,907
| – | – | ﹤0.01% | 4876 |
|
|
2021
Q4 | $78K | Hold |
33,907
| – | – | ﹤0.01% | 4625 |
|
|
2021
Q3 | $155K | Buy |
33,907
+9,100
| +37% | +$40K | ﹤0.01% | 4439 |
|
|
2021
Q2 | $110K | Sell |
24,807
-208,732
| -89% | -$1.06M | ﹤0.01% | 4342 |
|
|
2021
Q1 | $1.7M | Buy |
233,539
+18,781
| +9% | +$155K | ﹤0.01% | 3499 |
|
|
2020
Q4 | $1.64M | Buy |
214,758
+57,093
| +36% | +$382K | ﹤0.01% | 3435 |
|
|
2020
Q3 | $1.43M | Sell |
157,665
-420
| -0.3% | -$3.19K | ﹤0.01% | 3326 |
|
|
2020
Q2 | $1.34M | Buy |
158,085
+30,845
| +24% | +$203K | ﹤0.01% | 3329 |
|
|
2020
Q1 | $629K | Sell |
127,240
-208
| -0.2% | -$1.62K | ﹤0.01% | 3402 |
|
|
2019
Q4 | $918K | Buy |
127,448
+8,175
| +7% | +$73.9K | ﹤0.01% | 3424 |
|
|
2019
Q3 | $1.29M | Sell |
119,273
-652
| -0.5% | -$6.97K | ﹤0.01% | 3347 |
|
|
2019
Q2 | $1.56M | Buy |
119,925
+51,478
| +75% | +$683K | ﹤0.01% | 3329 |
|
|
2019
Q1 | $676K | Buy |
68,447
+8,329
| +14% | +$77.6K | ﹤0.01% | 3404 |
|
|
2018
Q4 | $625K | Buy |
+60,118
| New | +$726K | ﹤0.01% | 3414 |
|
State Street's LOGC Position: Q4 2022 in Review
State Street sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 33,907 shares — an estimated $9K sold.
State Street first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $1.7M in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- State Street reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- State Street sold 33,907 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $9K.
- State Street first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- State Street's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.7M in Q1 2021.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.